Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect.

Institute of Cell Biology, Eidgenössische Technische Hochschule (ETH) Zürich, Zürich, Switzerland.
The American Journal of Human Genetics (Impact Factor: 10.99). 02/2011; 88(2):162-72. DOI: 10.1016/j.ajhg.2011.01.008
Source: PubMed

ABSTRACT Neuromuscular junctions (NMJs) are synapses that transmit impulses from motor neurons to skeletal muscle fibers leading to muscle contraction. Study of hereditary disorders of neuromuscular transmission, termed congenital myasthenic syndromes (CMS), has helped elucidate fundamental processes influencing development and function of the nerve-muscle synapse. Using genetic linkage, we find 18 different biallelic mutations in the gene encoding glutamine-fructose-6-phosphate transaminase 1 (GFPT1) in 13 unrelated families with an autosomal recessive CMS. Consistent with these data, downregulation of the GFPT1 ortholog gfpt1 in zebrafish embryos altered muscle fiber morphology and impaired neuromuscular junction development. GFPT1 is the key enzyme of the hexosamine pathway yielding the amino sugar UDP-N-acetylglucosamine, an essential substrate for protein glycosylation. Our findings provide further impetus to study the glycobiology of NMJ and synapses in general.

Download full-text


Available from: Ariana Kariminejad, Jun 20, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in DPAGT1 are a newly recognised cause of congenital myasthenic syndrome. DPAGT1 encodes an early component of the N-linked glycosylation pathway. Initially mutations in DPAGT1 have been associated with the onset of the severe multisystem disorder - congenital disorder of glycosylation type 1J. However, recently it was established that certain mutations in this gene can cause symptoms restricted to muscle weakness resulting from defective neuromuscular transmission. We report four cases from a large Iranian pedigree with prominent limb-girdle weakness and minimal craniobulbar symptoms who harbour a novel mutation in DPAGT1, c.652C>T, p.Arg218Trp. This myasthenic syndrome may mimic myopathic disorders and is likely under-diagnosed.
    Neuromuscular Disorders 04/2013; 23(6). DOI:10.1016/j.nmd.2013.03.003 · 3.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Congenital myasthenic syndromes are a heterogeneous group of inherited disorders that arise from impaired signal transmission at the neuromuscular synapse. They are characterized by fatigable muscle weakness. We performed linkage analysis, whole-exome and whole-genome sequencing to determine the underlying defect in patients with an inherited limb-girdle pattern of myasthenic weakness. We identify ALG14 and ALG2 as novel genes in which mutations cause a congenital myasthenic syndrome. Through analogy with yeast, ALG14 is thought to form a multiglycosyltransferase complex with ALG13 and DPAGT1 that catalyses the first two committed steps of asparagine-linked protein glycosylation. We show that ALG14 is concentrated at the muscle motor endplates and small interfering RNA silencing of ALG14 results in reduced cell-surface expression of muscle acetylcholine receptor expressed in human embryonic kidney 293 cells. ALG2 is an alpha-1,3-mannosyltransferase that also catalyses early steps in the asparagine-linked glycosylation pathway. Mutations were identified in two kinships, with mutation ALG2p.Val68Gly found to severely reduce ALG2 expression both in patient muscle, and in cell cultures. Identification of DPAGT1, ALG14 and ALG2 mutations as a cause of congenital myasthenic syndrome underscores the importance of asparagine-linked protein glycosylation for proper functioning of the neuromuscular junction. These syndromes form part of the wider spectrum of congenital disorders of glycosylation caused by impaired asparagine-linked glycosylation. It is likely that further genes encoding components of this pathway will be associated with congenital myasthenic syndromes or impaired neuromuscular transmission as part of a more severe multisystem disorder. Our findings suggest that treatment with cholinesterase inhibitors may improve muscle function in many of the congenital disorders of glycosylation.
    Brain 03/2013; 136(Pt 3):944-56. DOI:10.1093/brain/awt010 · 10.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tubular aggregate myopathy (TAM) is a hereditary muscle disorder that is pathologically characterized by the presence of tubular aggregates. The responsible genes have not been clarified for many individuals affected by TAM. In order to identify the genetic cause of TAM, we performed whole exome sequencing in genomic DNA from 2 families affected by dominant TAM with hypocalcemia. We identified one common variant in both families, heterozygous missense mutation, c.292G>A (Gly98Ser) in ORAI1. We also found an additional heterozygous missense mutation, c.412C>T (p.Leu138Phe) in ORAI1, in the third TAM family by Sanger sequencing. The mutations were not listed in dbSNP137, 1000genomes, or Human Genetic Variation Database collecting Japanese genetic variations. Orai1 is a cell-surface transmembrane protein which acts as a store-operated Ca2+ channel, is highly expressed in the skeletal muscles. The store-operated Ca2+ channel is activated by diminished luminal Ca2+ levels in the sarcoplasmic reticulum via the activation of stromal interaction molecule 1 (STIM1) sensing of Ca2+ depletion. We demonstrated that skeletal myotubes from an affected individual and HEK293 cells expressing mutated Orai1 proteins displayed spontaneous extracellular Ca2+ entry into cells independent of STIM1 activation. Our results indicated that calcium entry into myofibers via store-operated Ca2+ channels were constitutively activated by dominant mutations in ORAI1 that cause altered Ca2+ homeostasis, resulting in tubular aggregate myopathy with hypocalcemia. Recently, dominant mutations in STIM1 have been identified to cause tubular aggregate myopathy. Together, these results strongly suggest that the constitutive extracellular Ca2+ entry caused by a mutation in either the STIM1 or ORAI1 is associated with a certain type of tubular aggregate myopathy.
    Neuromuscular Disorders 10/2014; 24(s 9–10):792. DOI:10.1093/hmg/ddu477 · 3.13 Impact Factor